Pharmaceutical composition

a technology of pharmaceutical compositions and compositions, applied in the field of pharmaceutical compositions, can solve the problems of insufficient vaccine effect, public health problems, and insufficient therapeutic effect of vaccines

Inactive Publication Date: 2010-12-30
NAKAMORI PHARMA
View PDF1 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0034]The pharmaceutical composition of the present invention has various drug efficacies.

Problems solved by technology

Antibiotics and synthetic antibacterial agents are used as therapeutic drugs for bacterial diseases among them, but resistant bacteria to these antibacterial agents have appeared, and no sufficient therapeutic effect has been obtained.
In addition, public health problems have occurred because the drugs used remain in the bodies of domestic animals.
Vaccines have been used for some viral diseases in domestic animals and domestic fowl, but the effect of the vaccine is not sufficient as seen in an example of chicken infectious bronchitis.
Such a breeding method burdens domestic animals with great stress.
As with human beings, excessive stress also brings an abnormality to the autonomic nervous system, resulting in occurrences of problems such as immune abnormality including allergic diseases, and constipation in domestic animals.
Also, constipation not only has a problem that a stool is not excreted, but also if the constipation persists, the constipation itself becomes stress to lose balance in the autonomic nervous system.
Therapeutic drugs for constipation include magnesium sulfate, magnesium oxide and glauber's salt, but these have potential side effects, e.g., if they are taken in a large amount, symptoms of poisoning rarely occur and if they are taken in a large amount for a long period of time, hypermagnesemia occurs.
Also, phenolphthalein-based large intestine stimulative purgatives include phenovalin, bisacodyl and sodium picosulfate, but they have the potential for side effects such as nausea, emesis and abdominal pain.
Also materials such as lactobacillus and dietary fibers derived from safe foods are available, but their effects cannot always be said to be sufficient, and new materials have been required.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0035]The pharmaceutical composition of the present invention is one in which 17 kinds of Chinese crude drugs have been blended, and has 1.5 parts by weight powdered fennel, 2.0 parts by weight powdered rhubarb, 1.0 part by weight powdered glycyrrhiza, 2.0 parts by weight powdered phellodendron bark, 1.0 part by weight powdered zedoary, 1.5 parts by weight powdered picrasma wood, 1.0 part by weight powdered matricaria chamomilla, 1.5 parts by weight powdered geranium herb, 1.0 part by weight powdered ginseng, 1.5 parts by weight powdered citrus unshiu peel, 1.0 part by weight powdered scutellaria root, 1.0 part by weight powdered magnolia bark, 2.0 parts by weight powdered oyster shell, 1.0 part by weight powdered cyperus rhizome, 2.0 parts by weight powdered platycodon root, 2.0 parts by weight powdered melia azedarach, 1.0 part by weight powdered cnidium rhizome, 2.0 parts by weight sodium bicarbonate and 4.0 parts by weight precipitated calcium carbonate in 30 parts by weight of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A pharmaceutical composition comprising 1.5 parts by weight powdered fennel, 2.0 parts by weight powdered rhubarb, 1.0 part by weight powdered glycyrrhiza, 2.0 parts by weight powdered phellodendron bark, 1.0 part by weight powdered zedoary, 1.5 parts by weight powdered picrasma wood, 1.0 part by weight powdered matricaria chamomilla, 1.5 parts by weight powdered geranium herb, 1.0 part by weight powdered ginseng, 1.5 parts by weight powdered citrus unshiu peel, 1.0 part by weight powdered scutellaria root, 1.0 part by weight powdered magnolia bark, 2.0 parts by weight powdered oyster shell, 1.0 part by weight powdered cyperus rhizome, 2.0 parts by weight powdered platycodon root, 2.0 parts by weight powdered melia azedarach, 1.0 part by weight powdered cnidium rhizome, 2.0 parts by weight sodium bicarbonate and 4.0 parts by weight precipitated calcium carbonate in 30 parts by weight of the composition.

Description

TECHNICAL FIELD[0001]The present invention relates to a pharmaceutical composition, and particularly relates to the pharmaceutical composition which is applied to cattle, horses, swine, sheep, goats, dogs, cats, chickens, domestic ducks, turkeys, wild ducks, ostriches and the like.BACKGROUND ART[0002]As diseases of domestic animals such as cattle, swine and chickens, the incidence of calf scours, swine pleural pneumonia and atrophic rhinitis, and chicken infectious bronchitis and colibacillosis are high. Antibiotics and synthetic antibacterial agents are used as therapeutic drugs for bacterial diseases among them, but resistant bacteria to these antibacterial agents have appeared, and no sufficient therapeutic effect has been obtained. In addition, public health problems have occurred because the drugs used remain in the bodies of domestic animals. Thus, preventive measures that do not depend on chemical therapy have been desired.[0003]Vaccines have been used for some viral diseases...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K33/10A61P11/00A61K36/00A61K36/18A61K36/185A61K36/234A61K36/235A61K36/258A61K36/28A61K36/346A61K36/484A61K36/539A61K36/57A61K36/58A61K36/708A61K36/752A61K36/756A61K36/8905A61K36/9066
CPCA61K36/00A61K36/28A61K36/8905A61K33/00A61K35/618A61K36/185A61K36/234A61K36/235A61K36/258A61K36/9066A61K36/346A61K36/539A61K36/575A61K36/58A61K36/708A61K36/752A61K36/756A61K2300/00A61P1/00A61P11/00A61P17/00A61P31/04A61P31/10A61P31/12A61P33/02Y02A50/30
Inventor NAKAMORI, TOSHIO
Owner NAKAMORI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products